BetterLife Pharma Inc
Canadian Securities Exchange:BETRView on OTCQB

  • LAST PRICE
    0.1150
  • TODAY'S CHANGE (%)
    -0.0100 (-8.0000%)
  • Bid / Lots
    0.1200/ 15
  • Ask / Lots
    0.1250/ 48
  • Open / Previous Close
    0.1250 / 0.1250
  • Day Range
    0.1100
    0.1250
  • 52 Week Range
    0.0500
    0.1950
  • Volume
    14,885

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Oct 23, 2024

      Show headlines and story abstract

    • 8:00AM ET on Wednesday Oct 23, 2024 by Dow Jones
      Companies Mentioned: BETR

      BetterLife Obtains Favourable Genotoxicity Data for Oral BETR-001

      VANCOUVER, British Columbia, Oct. 23, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. ("BetterLife" or the "Company") (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic derivative of lysergic acid diethylamide ("LSD"), announced it has completed one of its IND-enabling genotoxicity studies of BETR-001. The studies demonstrated that oral BETR-001, even at very high doses, does not show any evidence of bone marrow toxicity or mutagenic (DNA mutation) and clastogenic (chromosome damage) activities.

Peers Headlines